Effect of somatostatin in advanced gastric cancer after D2 radical gastrectomy

Table 1 Clinical pathological indicator of patients in the trial group and the control group

	Trial group	Control group	Statistic value	P value
Age	56.3 ± 15.0	55.7 ± 14.7	0.209	0.835
Sex (male/female)	31:30	34:25	0.560	0.454
BMI	22.3 ± 5.0	23.0±4.7	0.861	0.391
Tumor size	4.7 ± 2.9	4.6 ± 3.1	0.325	0.746
T stage (T1/T2/T3/T4a)	0/15/28/18	0/13/29/19	0.187	0.911
Borrmann type (I/II/III/IV)	6/15/31/9	7/16/29/7	1.761	0.623
Histological type (differentiated/undifferentiated)	31/30	32/29	0.033	0.856
Operation time	207.7 ± 39.8	218.0 ± 56.5	1.152	0.252
Blood loss	211.3 ± 77.6	203.7 ± 54.6	0.617	0.538
Number of lymph nodes	29.3 ± 10.5	28.5 ± 8.6	0.479	0.633
Anastomotic method (billroth I/II Roux-en-Y)	0/35/26	0/34/25	0.146	0.702
Gastrectomy method (proximal/distal/total)	0/35/26	0/34/25	0.146	0.702
Lymph node dissection method (D2/D2PRO)	31/20	28/21	0.082	0.775
With organ resection (yes/no)	11/50	12/47	0.103	0.748
TNM stage (1/2/3/4)	0/18/33/10	0/16/32/9	0.050	0.975